Tenderwize
Back to tender search

Non-exclusive drug discount agreement for Vilanterol/Fluticasone

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Mar 31, 2028 · 540 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Vilanterol/Fluticason (ATC-Code nach WHO: R03AK10)

60/100

Opportunity Score

PromisingLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

60 / 100

Complexity

15 / 100

Risk factors

No guaranteed minimum purchase; actual revenue is uncertain and may be low.

The Open-House procedure may be terminated early if exclusive agreements are concluded, ending existing discount agreem...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Mar 31, 2028

Overview

Strong opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Supply of pharmaceutical products containing Vilanterol/Fluticasone (ATC R03AK10) under a non-exclusive discount agreement.
  • The agreement is open to all interested pharmaceutical companies that meet the participation requirements.
Show full summary

This is a non-exclusive drug discount agreement (Rabattvereinbarung) under § 130a Abs. 8 SGB V for the active substance Vilanterol/Fluticasone (ATC R03AK10) via an Open-House model. The contracting authority is AOK PLUS, covering Saxony and Thuringia. The procedure is not a classic public procurement but a voluntary transparency publication. No estimated value, no guaranteed purchase quantities, and no exclusivity. The agreement ends 31 March 2028. Submission via DTVP portal; first deadline 5 March 2026.

Risks

No guaranteed minimum purchase; actual revenue is uncertain and may be low.

The Open-House procedure may be terminated early if exclusive agreements are concluded, ending existing discount agreem...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal products.

Eligibility

  • Must submit a declaration of no conflict of interest (exclusion grounds per §§ 123, 124 GWB).

Administrative

  • Must submit a declaration regarding Russia sanctions (EU Regulation 833/2014).

Award Criteria

Lot 1

No explicit award criteria provided; the agreement is based on acceptance of predetermined discount terms.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Vilanterol/Fluticasone

Open-House model for non-exclusive discount agreements on pharmaceuticals containing Vilanterol/Fluticasone (ATC R03AK10). No exclusivity, no guaranteed minimum purchase. The agreement term ends 31 March 2028. Participation requires acceptance of the discount terms and confidentiality obligations.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Mar 2026 - Mar 2028

Category

Pharmaceutical products

Award Criteria

No explicit award criteria provided; the agreement is based on acceptance of predetermined discount terms.

Deadline

Expired Mar 05, 2026

Procurement Details

Publication date
15 Jan 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
32969-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30